These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37564229)

  • 21. Differentiation stage of myeloma plasma cells: biological and clinical significance.
    Paiva B; Puig N; Cedena MT; de Jong BG; Ruiz Y; Rapado I; Martinez-Lopez J; Cordon L; Alignani D; Delgado JA; van Zelm MC; Van Dongen JJ; Pascual M; Agirre X; Prosper F; Martín-Subero JI; Vidriales MB; Gutierrez NC; Hernandez MT; Oriol A; Echeveste MA; Gonzalez Y; Johnson SK; Epstein J; Barlogie B; Morgan GJ; Orfao A; Blade J; Mateos MV; Lahuerta JJ; San-Miguel JF
    Leukemia; 2017 Feb; 31(2):382-392. PubMed ID: 27479184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of cell morphology and immunophenotypic characteristics in 47 cases of multiple myeloma].
    Su XD; Lin R; Xu XL; Chen X; Zhan WL; Zheng JP; Fan CL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):137-41. PubMed ID: 25687061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.
    Muccio VE; Saraci E; Gilestro M; Gattei V; Zucchetto A; Astolfi M; Ruggeri M; Marzanati E; Passera R; Palumbo A; Boccadoro M; Omedè P
    Cytometry B Clin Cytom; 2016 Jan; 90(1):81-90. PubMed ID: 26287276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunophenotyping of plasma cells.
    Rawstron AC
    Curr Protoc Cytom; 2006 May; Chapter 6():Unit6.23. PubMed ID: 18770841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunophenotyping of leukemic cells in the diagnosis of hairy cell leukemia].
    Gotić M; Kraguljac N; RolovićZ ; Radosević N; Bosković D
    Srp Arh Celok Lek; 2000; 128(5-6):157-64. PubMed ID: 11089415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
    Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model.
    Cannizzo E; Carulli G; Del Vecchio L; Ottaviano V; Bellio E; Zenari E; Azzarà A; Petrini M; Preffer F
    Am J Clin Pathol; 2012 Mar; 137(3):377-86. PubMed ID: 22338049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.
    Pellat-Deceunynck C; Bataille R; Robillard N; Harousseau JL; Rapp MJ; Juge-Morineau N; Wijdenes J; Amiot M
    Blood; 1994 Oct; 84(8):2597-603. PubMed ID: 7522634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunophenotype in multiple myeloma cells detected by multiparameter flow cytometry].
    Cao FF; Chen F; Hu YP; Zhang JH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):620-3. PubMed ID: 22739168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
    Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
    Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
    Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters.
    Gupta S; Karandikar NJ; Ginader T; Bellizzi AM; Holman CJ
    Cytometry B Clin Cytom; 2018 May; 94(3):500-508. PubMed ID: 29316245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunophenotyping of selected hematologic disorders--focus on lymphoproliferative disorders with more than one malignant cell population.
    Porwit A
    Int J Lab Hematol; 2013 Jun; 35(3):275-82. PubMed ID: 23590655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry.
    Schouweiler KE; Karandikar NJ; Holman CJ
    Cytometry B Clin Cytom; 2019 Jul; 96(4):310-318. PubMed ID: 31140731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis.
    McSweeney PA; Wells DA; Shults KE; Nash RA; Bensinger WI; Buckner CD; Loken MR
    Blood; 1996 Jul; 88(2):622-32. PubMed ID: 8695810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias.
    Draxler DF; Wutzlhofer LM; Slavka G; Hübl W; Ludwig H; Schreder M; Reynolds J; Willheim M
    Indian J Hematol Blood Transfus; 2019 Oct; 35(4):673-682. PubMed ID: 31741619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
    Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
    Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients.
    Hu Y; Wang M; Chen Y; Chen X; Fang F; Liu S; Zhang Y; Wu X; Zhu P
    Chin Med J (Engl); 2014; 127(15):2765-70. PubMed ID: 25146610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.
    Paiva B; Gutiérrez NC; Chen X; Vídriales MB; Montalbán MÁ; Rosiñol L; Oriol A; Martínez-López J; Mateos MV; López-Corral L; Díaz-Rodríguez E; Pérez JJ; Fernández-Redondo E; de Arriba F; Palomera L; Bengoechea E; Terol MJ; de Paz R; Martin A; Hernández J; Orfao A; Lahuerta JJ; Bladé J; Pandiella A; Miguel JF;
    Leukemia; 2012 Aug; 26(8):1862-9. PubMed ID: 22333880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
    Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
    Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.